Clinical Trial Update: A Study to Evaluate RAF265, an Oral Drug Administered to Subjects With Locally Advanced or Metastatic Melanoma [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for RAF265 in locally advanced or metastatic melanoma across Phase 1 and Phase 2; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• RAF265

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Metastatic Melanoma | Phase 1, Phase 2 | Status: COMPLETED